Strategic support for biotech companies and IR teams to strengthen investor engagement across the fundraising lifecycle

We work closely with in-house investor relations teams, executive leadership, and IR firms to supplement communications efforts with scientific and strategic depth. Our role is to help biotech companies build credibility, articulate financing milestones, and prepare for meaningful engagement with investors, reinforcing the work of existing IR resources with targeted support.

Whether companies are preparing to raise capital, managing investor communications post-raise, or facing limited bandwidth, we provide strategic, targeted, and on-demand support that helps clarify positioning, strengthen valuation messaging, and frame development risks and opportunities. For IR firms supporting life science clients, our expertise enhances technical accuracy and sharpens investment narratives, helping to ensure investor-facing materials resonate with both scientific and financial audiences.

Who We Serve

  • Early-stage biotech companies pre- and post-raise
  • VC-backed companies managing investor expectations post-raise
  • Teams without in-house IR leadership or needing additional bandwidth
  • IR firms representing clients in need of deeper scientific and development expertise prior to VC engagement


With our support behind the scenes, IR teams can:

  • Deliver more credible, investor-facing narratives grounded in scientific and strategic insight
  • Manage the fundraising process with greater operational clarity and discipline
  • Maintain ownership of investor relationships while elevating preparedness and positioning
  • Strengthen investor trust and retention through well-executed communications across the funding lifecycle


Post-Raise & Ongoing Investor Communication Services

Following a successful raise, maintaining momentum with investors requires more than routine updates - it demands thoughtful, well-timed communication that reflects scientific progress and strategic intent. Alacrita works with biotech teams to shape meaningful milestone messaging, manage complex or evolving narratives, and sustain investor confidence through credible, insight-driven updates. For IR firms supporting life science clients, we act as an extension of your team, providing the scientific and development depth needed to deliver communications that resonate with sophisticated investor audiences.

We help biotech teams craft milestone communication strategies that resonate with investors and stakeholders. This includes planning for data disclosures, aligning messaging with scientific and commercial objectives, and ensuring that communications reinforce credibility and progress toward key inflection points.

Alacrita distills complex scientific and regulatory developments into clear, compelling narratives that support investor confidence. We help biotech companies articulate the rationale, implications, and significance of their progress in a way that aligns with expectations of sophisticated audiences.

We develop impactful board and stakeholder materials, including investor letters, progress decks, FAQs, and meeting content. Our support ensures updates are strategic, transparent, and aligned with ongoing development and fundraising narratives.

When timelines shift or data surprises arise, Alacrita helps biotech teams communicate with clarity and control. We provide strategic support for risk messaging, crisis response, and stakeholder engagement to protect credibility and maintain trust during challenging moments.

We conduct in-depth analysis of company positioning and investor perception to identify opportunities for narrative refinement and valuation alignment. Our insights help clients adjust messaging, clarify differentiators, and respond proactively to market feedback.

For lean biotech teams without in-house investor relations resources, Alacrita offers outsourced IR support by collaborating with trusted IR collaborators in tailoring to the needs of early-stage and venture-backed companies. We act as an extension of your team working with IR partners in managing IR communications and ensuring investor engagement remains strong and consistent.